Floatz logo

Ambrisentan

Hepatorenal Syndrome

Noorik Biopharmaceuticals AGSmall moleculePhase 2Active
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hepatorenal Syndrome cohort.

Asset / SponsorPhaseRating
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
Noorik Biopharmaceuticals AG
Phase 4A
NORMAL HUMAN SERUM ALBUMIN
Massachusetts General Hospital
Phase 4BBB
Norfloxacin
Hospital Clinic of Barcelona
Phase 4BB
Midodrine
University of California, Los Angeles
Phase 2/3BB
Octreotide Pamoate
University of California, Los Angeles
Phase 2/3BB

View all 11 →

Same molecule, other indications

Ambrisentan is also rated in:

pulmonary hypertensionDormant
CCC
Indicative ·
53 / 100
View asset →
cirrhosis of liverDormant
CCC
Indicative ·
52 / 100
View asset →
pulmonary hypertensionDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →